MSD scores second win in patent fight over Keytruda

The pharma giant invalidates a university's patent while gaining FDA approval for a new subcutaneous version of Keytruda as it protects its $29.5-billion-a-year cancer drug ahead of a looming patent cliff.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Patent cliff: 5 blockbusters running out of road

1 April 2025 MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.

Americas

Bernie Sanders blasts big pharma for ‘ripping off’ patients

8 February 2024 Senator criticises patent thickets and ‘monopolies’ ahead of senate hearing convened to interrogate CEOs | Sales of MSD’s blockbuster cancer treatment Keytruda rival McDonald’s annual revenue, says report.

Americas

MSD accuses university of patent contract breach

1 December 2022 Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.

More features

Scientist jumps from Jones Day to expand rival’s biotech offering

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

MSD scores second win in patent fight over Keytruda

More on this story

Editor's picks

Editor's picks

More features